Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement
The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emissi...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2021-05, Vol.100 (5), p.1221-1229 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1229 |
|---|---|
| container_issue | 5 |
| container_start_page | 1221 |
| container_title | Annals of hematology |
| container_volume | 100 |
| creator | Song, Moo-Kon Chung, Joo-Seop Lim, Sung-Nam Lee, Won-Sik Lee, Sang-Min Kim, Seong-Jang Shim, Hye-Kyung Lee, Seok-Mo |
| description | The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807,
p
= 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703,
p
= 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445,
p
< 0.001; OS, HR = 0.213, 95% CI = 0.092–0.491,
p
< 0.007), and high National Cancer Center Network-International Prognostic Index score (PFS, HR = 3.152, 95% CI = 1.732–5.734,
p
< 0.001; OS, HR = 2.457, 95% CI = 1.363–4.430,
p
= 0.003) were independently associated with survivals in the patients. Our data showed that EN MTV is a useful and novel prognostic parameter for predicting survival in DLBCL patients with EN involvement. |
| doi_str_mv | 10.1007/s00277-021-04498-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2506276540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512160157</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-fd52065e0f9affc467f2504dd167a09bfeb3625baf05d82079d2b8c94c4b6983</originalsourceid><addsrcrecordid>eNp9kT1vFDEQhi1ERI7AH6BAlmhoFsZef6xLOAKcdBEUJ1rL67UTR-v1Ye8mpOG34-TChyjiwpY8z7wz0oPQCwJvCIB8WwColA1Q0gBjqmvUI7QirKUN8I49RitQrWp4PcfoaSmXAIR2jD5Bx20rRVevFfq5HsMUrBnxJu6NnXHy-PTHnM2Uhvp55mbTpzFYvFtiyvhbGpfocJgwZYA_BO-X4vDW5HOH32PrxhFvb-L-IkWDv5o5uGku-DrMF_-GbqarNF65WIvP0JE3Y3HP798TtPt4ult_brZfPm3W77aNbSWfGz9wCoI78Mp4b5mQnnJgw0CENKB67_pWUN4bD3zoKEg10L6zilnWC9W1J-j1IXaf0_fFlVnHUG63NZNLS9E1TFApOIOKvvoPvUxLnupylSKUCCBcVooeKJtTKdl5vc8hmnyjCehbOfogR1c5-k6OVrXp5X300kc3_Gn5baMC7QEotTSdu_x39gOxvwDq7poU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512160157</pqid></control><display><type>article</type><title>Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Song, Moo-Kon ; Chung, Joo-Seop ; Lim, Sung-Nam ; Lee, Won-Sik ; Lee, Sang-Min ; Kim, Seong-Jang ; Shim, Hye-Kyung ; Lee, Seok-Mo</creator><creatorcontrib>Song, Moo-Kon ; Chung, Joo-Seop ; Lim, Sung-Nam ; Lee, Won-Sik ; Lee, Sang-Min ; Kim, Seong-Jang ; Shim, Hye-Kyung ; Lee, Seok-Mo</creatorcontrib><description>The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807,
p
= 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703,
p
= 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445,
p
< 0.001; OS, HR = 0.213, 95% CI = 0.092–0.491,
p
< 0.007), and high National Cancer Center Network-International Prognostic Index score (PFS, HR = 3.152, 95% CI = 1.732–5.734,
p
< 0.001; OS, HR = 2.457, 95% CI = 1.363–4.430,
p
= 0.003) were independently associated with survivals in the patients. Our data showed that EN MTV is a useful and novel prognostic parameter for predicting survival in DLBCL patients with EN involvement.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-021-04498-9</identifier><identifier>PMID: 33768337</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Extranodal Extension - diagnostic imaging ; Female ; Hematology ; Humans ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Medicine ; Medicine & Public Health ; Metabolism ; Middle Aged ; Oncology ; Original Article ; Positron-Emission Tomography ; Prognosis ; Retrospective Studies ; Survival Analysis ; Tomography ; Tumor Burden</subject><ispartof>Annals of hematology, 2021-05, Vol.100 (5), p.1221-1229</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-fd52065e0f9affc467f2504dd167a09bfeb3625baf05d82079d2b8c94c4b6983</citedby><cites>FETCH-LOGICAL-c375t-fd52065e0f9affc467f2504dd167a09bfeb3625baf05d82079d2b8c94c4b6983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-021-04498-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-021-04498-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33768337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Song, Moo-Kon</creatorcontrib><creatorcontrib>Chung, Joo-Seop</creatorcontrib><creatorcontrib>Lim, Sung-Nam</creatorcontrib><creatorcontrib>Lee, Won-Sik</creatorcontrib><creatorcontrib>Lee, Sang-Min</creatorcontrib><creatorcontrib>Kim, Seong-Jang</creatorcontrib><creatorcontrib>Shim, Hye-Kyung</creatorcontrib><creatorcontrib>Lee, Seok-Mo</creatorcontrib><title>Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807,
p
= 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703,
p
= 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445,
p
< 0.001; OS, HR = 0.213, 95% CI = 0.092–0.491,
p
< 0.007), and high National Cancer Center Network-International Prognostic Index score (PFS, HR = 3.152, 95% CI = 1.732–5.734,
p
< 0.001; OS, HR = 2.457, 95% CI = 1.363–4.430,
p
= 0.003) were independently associated with survivals in the patients. Our data showed that EN MTV is a useful and novel prognostic parameter for predicting survival in DLBCL patients with EN involvement.</description><subject>Adult</subject><subject>Aged</subject><subject>Extranodal Extension - diagnostic imaging</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - diagnostic imaging</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tomography</subject><subject>Tumor Burden</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kT1vFDEQhi1ERI7AH6BAlmhoFsZef6xLOAKcdBEUJ1rL67UTR-v1Ye8mpOG34-TChyjiwpY8z7wz0oPQCwJvCIB8WwColA1Q0gBjqmvUI7QirKUN8I49RitQrWp4PcfoaSmXAIR2jD5Bx20rRVevFfq5HsMUrBnxJu6NnXHy-PTHnM2Uhvp55mbTpzFYvFtiyvhbGpfocJgwZYA_BO-X4vDW5HOH32PrxhFvb-L-IkWDv5o5uGku-DrMF_-GbqarNF65WIvP0JE3Y3HP798TtPt4ult_brZfPm3W77aNbSWfGz9wCoI78Mp4b5mQnnJgw0CENKB67_pWUN4bD3zoKEg10L6zilnWC9W1J-j1IXaf0_fFlVnHUG63NZNLS9E1TFApOIOKvvoPvUxLnupylSKUCCBcVooeKJtTKdl5vc8hmnyjCehbOfogR1c5-k6OVrXp5X300kc3_Gn5baMC7QEotTSdu_x39gOxvwDq7poU</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Song, Moo-Kon</creator><creator>Chung, Joo-Seop</creator><creator>Lim, Sung-Nam</creator><creator>Lee, Won-Sik</creator><creator>Lee, Sang-Min</creator><creator>Kim, Seong-Jang</creator><creator>Shim, Hye-Kyung</creator><creator>Lee, Seok-Mo</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20210501</creationdate><title>Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement</title><author>Song, Moo-Kon ; Chung, Joo-Seop ; Lim, Sung-Nam ; Lee, Won-Sik ; Lee, Sang-Min ; Kim, Seong-Jang ; Shim, Hye-Kyung ; Lee, Seok-Mo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-fd52065e0f9affc467f2504dd167a09bfeb3625baf05d82079d2b8c94c4b6983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Extranodal Extension - diagnostic imaging</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - diagnostic imaging</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tomography</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Moo-Kon</creatorcontrib><creatorcontrib>Chung, Joo-Seop</creatorcontrib><creatorcontrib>Lim, Sung-Nam</creatorcontrib><creatorcontrib>Lee, Won-Sik</creatorcontrib><creatorcontrib>Lee, Sang-Min</creatorcontrib><creatorcontrib>Kim, Seong-Jang</creatorcontrib><creatorcontrib>Shim, Hye-Kyung</creatorcontrib><creatorcontrib>Lee, Seok-Mo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Moo-Kon</au><au>Chung, Joo-Seop</au><au>Lim, Sung-Nam</au><au>Lee, Won-Sik</au><au>Lee, Sang-Min</au><au>Kim, Seong-Jang</au><au>Shim, Hye-Kyung</au><au>Lee, Seok-Mo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>100</volume><issue>5</issue><spage>1221</spage><epage>1229</epage><pages>1221-1229</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807,
p
= 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703,
p
= 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445,
p
< 0.001; OS, HR = 0.213, 95% CI = 0.092–0.491,
p
< 0.007), and high National Cancer Center Network-International Prognostic Index score (PFS, HR = 3.152, 95% CI = 1.732–5.734,
p
< 0.001; OS, HR = 2.457, 95% CI = 1.363–4.430,
p
= 0.003) were independently associated with survivals in the patients. Our data showed that EN MTV is a useful and novel prognostic parameter for predicting survival in DLBCL patients with EN involvement.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33768337</pmid><doi>10.1007/s00277-021-04498-9</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2021-05, Vol.100 (5), p.1221-1229 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2506276540 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Extranodal Extension - diagnostic imaging Female Hematology Humans Lymphoma Lymphoma, Large B-Cell, Diffuse - diagnostic imaging Lymphoma, Large B-Cell, Diffuse - metabolism Lymphoma, Large B-Cell, Diffuse - pathology Male Medicine Medicine & Public Health Metabolism Middle Aged Oncology Original Article Positron-Emission Tomography Prognosis Retrospective Studies Survival Analysis Tomography Tumor Burden |
| title | Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A44%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Impact%20of%20Extranodal%20Metabolic%20Tumor%20Volume%20in%20240%20Diffuse%20Large%20B%20cell%20Lymphoma%20Patients%20with%20Extranodal%20Involvement&rft.jtitle=Annals%20of%20hematology&rft.au=Song,%20Moo-Kon&rft.date=2021-05-01&rft.volume=100&rft.issue=5&rft.spage=1221&rft.epage=1229&rft.pages=1221-1229&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-021-04498-9&rft_dat=%3Cproquest_cross%3E2512160157%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512160157&rft_id=info:pmid/33768337&rfr_iscdi=true |